62538-16-3

Usage

Derivative of pyrazole

The compound is a modified version of the pyrazole ring, which is a five-membered ring system with one nitrogen atom.

4-fluorophenyl substituent

The compound contains a phenyl ring (a six-membered carbon ring with delocalized electrons) with a fluorine atom attached to the fourth position (4-position).

5-methyl substituent

The compound also contains a methyl group (a carbon atom with three hydrogen atoms attached) attached to the fifth position (5-position) of the pyrazole ring.

Biological activity

Research has shown that the compound has the ability to inhibit certain enzymes and receptors, indicating its potential as a therapeutic agent.

Interest in drug discovery and pharmaceuticals

The compound's biological activity and potential pharmacological applications make it of interest for further research and development in the field of drug discovery and pharmaceuticals.

Upstream product

• 459-22-3 4-fluorophenylacetonitrile 
• 447-03-0 2-(4-fluorophenyl)-3-oxobutanenitrile 
• 18871-66-4 N,N-dimethylacetamide dimethyl acetal 

Downstream Products

• 879623-71-9 3-(4-fluorophenyl)-8-(4-methoxyphenyl)-2-methyl-8,9-dihydropyrazolo[1,5-a]quinazolin-6(7H)-one 
• 1404449-60-0 3-(4-fluorophenyl)-2-methylpyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-dione 
• 1404447-07-9 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(4-fluorophenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1404447-03-5 3-(4-fluorophenyl)-2-methyl-5-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1404447-09-1 3-(4-fluorophenyl)-2-methyl-5-(quinolin-6-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 901715-05-7 ethyl 4-(3-(4-fluorophenyl)-7-hydroxy-2-methylpyrazolo[1,5-a]-pyrimidin-5-yl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

Pyrazolopyrimidines as Potent Stimulators for Transient Receptor Potential Canonical 3/6/7 Channels

Transient receptor potential canonical 3/6/7 (TRPC3/6/7) are highly homologous receptor-operated nonselective cation channels. Despite their physiological significance, very few selective and potent agonists are available for functional examination of these channels. Using a cell-based high throughput screening approach, a lead compound with the pyrazolopyrimidine skeleton was identified as a TRPC6 agonist. Synthetic schemes for the lead and its analogues were established, and structural-activity relationship studies were carried out. A series of potent and direct agonists of TRPC3/6/7 channels were identified, and among them, 4m-4p have a potency order of TRPC3 > C7 > C6, with 4n being the most potent with an EC50 of 20 nM on TRPC3. Importantly, these compounds exhibited no stimulatory activity on related TRP channels. The potent and selective compounds described here should be suitable for evaluation of the roles of TRPC channels in the physiology and pathogenesis of diseases, including glomerulosclerosis and cancer.

A pyrazolo [1,5-a] pyrimidine derivative and its anti-tumor use

The present invention relates to a pyrazolo[1,5-a]pyrimidine derivative of general formula 1 and a pharmaceutically acceptable salt thereof. The present invention also relates to use of compounds of formula 1 in the preparation of an anti-tumor medicament.

PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVE AND USE OF ANTI-TUMOR THEREOF

The present invention relates to a pyrazolo[1,5-a]pyrimidine derivative of general formula 1 and a pharmaceutically acceptable salt thereof. The present invention also relates to use of compounds of formula 1 in the preparation of an anti-tumor medicament.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.